Last reviewed · How we verify
Rosuvastatin plus clopidogrel
Rosuvastatin reduces cholesterol synthesis while clopidogrel inhibits platelet aggregation, together reducing cardiovascular risk through lipid lowering and antiplatelet effects.
Rosuvastatin reduces cholesterol synthesis while clopidogrel inhibits platelet aggregation, together reducing cardiovascular risk through lipid lowering and antiplatelet effects. Used for Secondary prevention of cardiovascular events in patients with acute coronary syndrome or stable coronary artery disease, Reduction of cardiovascular mortality and morbidity in high-risk patients.
At a glance
| Generic name | Rosuvastatin plus clopidogrel |
|---|---|
| Also known as | Crestor & Plavix |
| Sponsor | Federal University of São Paulo |
| Drug class | Statin plus antiplatelet agent combination |
| Target | HMG-CoA reductase; P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Rosuvastatin is an HMG-CoA reductase inhibitor that lowers LDL cholesterol and triglycerides while raising HDL cholesterol. Clopidogrel is a P2Y12 platelet receptor antagonist that prevents thrombotic events. The combination addresses both atherosclerotic plaque formation and thrombotic complications in cardiovascular disease.
Approved indications
- Secondary prevention of cardiovascular events in patients with acute coronary syndrome or stable coronary artery disease
- Reduction of cardiovascular mortality and morbidity in high-risk patients
Common side effects
- Bleeding
- Muscle pain or myalgia
- Elevated liver enzymes
- Dyspepsia
- Headache
Key clinical trials
- Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial (NA)
- A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI) (PHASE3)
- Concomitant Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Moderate and Moderate-to-severe Stroke (PHASE3)
- Combining Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Large-vessel Ischemic Stroke (PHASE3)
- Polypill in Acute Coronary Syndrome (PHASE2)
- Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease (PHASE2)
- Effect of Enhanced External Counterpulsation (NA)
- Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rosuvastatin plus clopidogrel CI brief — competitive landscape report
- Rosuvastatin plus clopidogrel updates RSS · CI watch RSS
- Federal University of São Paulo portfolio CI